All In Biotech

Drug Trial Radar · NCT04363801

A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients With Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish)

Last checked: Nov 19, 2026Latest source record: Oct 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 247 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

247

Actual

Start

Jul 29, 2020

Primary completion

Mar 31, 2025

Study completion Mar 31, 2025

Sponsor

Lead sponsor
Leap Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
BeiGene
First posted
Apr 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Conditions

  • Gastric Cancer
  • Gastric Adenocarcinoma
  • GastroEsophageal Cancer

Interventions

  • DKN-01 300mgDrug

    Administered by IV infusion

  • DKN-01 600mgDrug

    Administered by IV infusion

  • DKN-01 400mgDrug

    Administered by IV infusion

  • Tislelizumab 200mgDrug

    Administered by IV infusion

  • Tislelizumab 400mgDrug

    Administered by IV infusion

  • OxaliplatinDrug

    Administered by IV infusion

  • Capecitabine 1000mg/ m2 twice daily (BID)Drug

    Administered orally

  • Leucovorin CalciumDrug

    Administered by IV infusion

  • FluorouracilDrug

    Administered by IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A and B: Safety and Tolerability of DKN-01 in G/GEJ PatientsTime frame: approximately 28 months
  2. Part C: Progression Free Survival (PFS) in G/GEJ DKK1 High and Overall Patients Treated With DKN-01 in Combination With Tislelizumab and Chemotherapy vs Tislelizumab and Chemotherapy as a First-line TherapyTime frame: approximately 30 months

Locations

48 sites in 3 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Cancer Center

    Phoenix, Arizona

  • University of Arizona

    Tucson, Arizona

  • City of Hope

    Duarte, California

  • The Angeles Clinic Research Institute - A Cedars-Sinai Affiliate

    Los Angeles, California

  • University of Southern California

    Los Angeles, California

  • UCLA

    Los Angeles, California

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

  • Chao Family Comprehensive Cancer Center, University of California, Irvine

    Orange, California

  • University of California San Francisco

    San Francisco, California

  • Mayo Clinic Florida

    Jacksonville, Florida

  • AdventHealth Cancer Institute

    Orlando, Florida

  • Northwestern University Robert H. Lurie Comprehensive Cancer Center

    Chicago, Illinois

  • University of Chicago

    Chicago, Illinois

  • Pontchartrain Cancer Center

    Covington, Louisiana

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Columbia University Irving Medical Center

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Rhode Island Hospital

    Providence, Rhode Island

  • MD Anderson Cancer Center

    Houston, Texas

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsin

  • Charité Universitätsmedizin Berlin

    Berlin, Germany

  • Institut Fur Klinisch Onkologische Forschung Am Krankenhaus Nordwest

    Frankfurt, Germany

  • Hämatologisch-Onkologische Praxis Eppendorf (HOPE)

    Hamburg, Germany

  • Universitatsklinikum Heidelberg

    Heidelberg, Germany

  • Slk-Kliniken

    Heilbronn, Germany

  • Studienzentrum Onkologie Ravensburg

    Ravensburg, Germany

  • Caritas Klinikum Saarbrücken St. Theresia

    Saarbrücken, Germany

  • Korea University Ansan Hospital

    Ansan-si, South Korea

  • Hallym University Sacred Heart Hospital

    Anyang, South Korea

  • Dong-A University Hospital

    Busan, South Korea

  • National Cancer Center

    Goyang, South Korea

  • Gachon University Gil Medical Center

    Incheon, South Korea

  • Inha University Hospital

    Incheon, South Korea

  • Seoul National University Bundang Hospital

    Seongnam, South Korea

  • Korea University Anam Hospital

    Seoul, South Korea

  • Hanyang University Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.